Company News

Share this article:

Pfizer and Bausch & Lomb announced a co-promotion deal for both companies' prescription ophthalmic pharmaceuticals in the US. The five year agreement includes Pfizer's Xalatan, and Bausch & Lomb's Alrex, Lotemax, Zylet, and the company's investigational anti-infective eye drop, besifloxacin ophthalmic suspension (0.6%), which is currently under FDA review.

Pfizer has entered into agreements with Aurobindo Pharma, an India-based pharmaceutical company, to commercialize generic medications in the US and Europe. The move progresses the company's established products business unit, which is focused on the commercialization of products where market exclusivity has been lost.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.